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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disease of hemopoietic stem cell (HSC) origin resulting from the chromosomal translocation t(9;22)(q34;q11) that gives rise to the fusion gene, BCR-ABL1. ABL tyrosine kinase inhibitors (TKI) lead to long-term remission in the majority of CML patients, but approximately 50% of cases relapse when treatment is discontinued, as TKI are unable to fully eradicate quiescent stem/progenitor cells (SPC), [1] [2] [3] [4] [5] [6] [7] [8] [9] despite being able to inhibit BCR-ABL signaling in these cells. 6, 9, 10 Investigations have demonstrated that TKI-resistant SPC in patients show reduced levels of BCR-ABL1 expression as compared to baseline, and exhibit a more primitive, quiescent transcriptional signature that becomes predominant over time in response to TKI therapy. [11] [12] [13] [14] It is not currently known whether this quiescent signature is driven by CML SPC intrinsic signaling by the microenvironment, or by a combination of both.
One possible candidate for cell intrinsic regulation of the quiescent CML phenotype is the transcription factor E2F1, which regulates cell proliferation by activating genes important for G1-S-phase progression. 15 In mice, deletion of E2f1 resulted in increased T-cell numbers, 16, 17 whilst combined loss of E2f1/2/3 affected mature hemopoietic cell proliferation 18, 19 and survival of the myeloid lineage, 16 ,20 yet no effect was demonstrated on HSC function. 21, 22 In CML, E2F3 was shown to be important for disease initiation 23 and silencing of E2F1 in K562 cells or CD34 + cells led to activation of PP2A and BCR-ABL1 suppression. 24 In mouse fibroblasts, triple inactivation of E2f1/2/3 led to p53 activation and cell cycle arrest, 25 while deletion of p53 restored E2F1 transcriptional activity. 26 In recent work we have demonstrated that p53 acts as a key signaling hub to maintain survival of CML SPC. 27 As BCR-ABL had previously been shown to modulate miRNA levels, 28 to gain insight into how CML SPCs maintain quiescence, we investigated novel and publicly deposited mRNA/microRNA (miRNA) transcriptomic datasets derived from primitive human CML SPC. 27, [29] [30] [31] [32] [33] [34] Here we show that in CML SPC, the cancer-related miRNA hsa-mir183 is highly expressed in a BCR-ABL1-dependent manner and hypothesize that this miRNA deregulates specific SPC intrinsic mechanisms. Interestingly, it has been reported that hsa-mir183 targets EGR1, a member of the immediate early response transcription factor family that regulates proliferation and mobilization of normal SPC. The genetic network regulated by EGR1 responsible for stem cell division and migration has not been entirely elucidated. Interestingly, EGR1 loss has been shown to promote development of BCR-ABL1-mediated leukemia, while constitutive Egr1 is able to override leukemia conferred by deregulated E2F1 leukaemic cells. 35, 36, 37 Furthermore, it has recently been shown that genetic deletion of Egr1 accelerates BCR-ABL1-driven CML. 38 Here, we identify a novel CML-specific pathway in which BCR-ABL1 protein kinase regulates hsa-mir183-mediated inhibition of EGR1 leading to up-regulation of E2F1. In addition, we investigate the role that hsa-mir183/EGR1-mediated E2F1 expression plays in priming proliferation in CML SPC.
Methods
Cell isolation and culture. 44 For miRNA data, cDNA was hybridized to a miRNA chip based on Sanger miRBase Release 14 (LC Sciences, Texas) and normalized using a LOWESS (Locally-weighted Regression) method on the background-subtracted data. Raw data are publicly available via ArrayExpress (accession E-MTAB-3220) and normalized data are provided in Table S1 . The resulting miRNA data were analyzed using LIMMA. Monoclonal antibodies against CD45.1 and CD45.2 were used. For C-kit + (CD117 + ) cell isolation, BM cells were passed through MACS separation columns (Miltenyi Biotec, UK) using manufacturer's instructions. C-kit enriched cells were isolated using FACS Aria cell sorter (Becton Dickinson).
Statistics
Statistical analyses were performed using the Student's t test. A threshold of P<.05 was defined as statistically significant (*). Levels of P<.01 (**) and P<.001 (***) were taken to be highly statistically significant.
Study approval
All animal experiments were carried out according to UK Home Office regulations.
Results
CML SPC are predominantly quiescent despite expressing active BCR-ABL1
BCR-ABL1 confers a proliferative advantage to primitive CML cells. 32 To investigate cell cycle status, SPC (CD34 + 38 -) and more mature cells (CD34 + 38 + ) were isolated from primary normal and CML CP samples ( Figure 1Ai ). As previously reported, CML SPC expressed high levels of BCR-ABL1 ( Figure 1Aii ) when compared to more mature cells prior to treatment. 40, 48, 49 Despite this, CML SPC showed no significant difference in the percentage of quiescent cells (Figure 1Bi -ii, replicates shown in Figure S1A ). Similarly, mRNA levels of the cell cycle inhibitors p21, p27, p57 and protein levels of p21 and p27
did not differ between normal and CML SPC (Figure S1B suggesting that CML SPC are "primed to proliferate", as previously reported. 50 Consistent with the published literature, 6,9,10 BCR-ABL1 activity is affected by treatment with TKI in SPCs, as evidenced by a decrease in the levels of its downstream targets phospho-STAT5 and phospho-AKT ( Figure S1D ). While CML CD34 + 38 -SPC showed lower levels of BCL2 and less phosphorylation of AKT and STAT5 compared to mature CML CD34 + 38 + cells, these levels were still higher than in the equivalent population of normal cells ( Figure 1C ).
BCR-ABL1 regulates hsa-mir183 and EGR1 in CML SPC
BCR-ABL1 modulates the expression of miRNAs, 28 therefore to elaborate networks that may regulate SPC quiescence, we performed global miRNA expression profiling in normal and CML SPC. Several miRNAs were differentially expressed, including hsa-mir183 which was up-regulated in CML ( Figure 2A ). Validation by OncoMir array confirmed that hsa-mir183 was significantly up-regulated by 38-fold in CML versus normal SPC (Figure 2Bi -ii). The up-regulation of hsa-mir183 was BCR-ABL1 kinase dependent as its expression decreased upon treatment with TKIs ( Figure 2C ).
Published evidence, 35, 36 together with computational target prediction by the miRWalk database, 51 indicated that hsa-mir183 targets and down-regulates EGR1, which plays a role in normal SPC proliferation and development of BCR-ABL1-mediated leukemia. As predicted, EGR1 mRNA levels were significantly lower in CML versus normal SPC ( Figure 2Di ). This effect appeared to be BCR-ABL dependent as primary CML CD34 + cells demonstrated a significant increase in EGR1 expression following long term exposure to TKI (p=0.01; Figure 2Dii ). To further confirm that the regulation of EGR1
was hsa-mir183 dependent, hsa-mir183 expression was knocked-down in CML SPC using a GFP-lentiviral-based anti-miRNA. GFP + SPC were analyzed for the level of the EGR1 transcripts, the expression of which was rescued by hsa-mir183 knockdown ( Figure 2E ). In addition, we found that SPC with hsa-mir183 knock-down proliferated less than control cells ( Figure 2F ) and generated fewer colonies in CFC assays ( Figure   2G ).
To prove direct binding between hsa-mir183 and EGR1 in CML cells, we generated oligos complementary to the EGR1 3'UTR (WT) encompassing the binding site for hsamir183 ( Figure S1F ). As a control, a mutated version of the binding site was designed by inserting a BamHI restriction site. Both oligos were transfected into CML KCL22 cells, together with either 50nM hsa-mir183 mimic or a negative control. After 48hrs, cell lysates showed a significant decrease in luciferase signal in the cells containing the WT EGR1 sequence and the hsa-mir183 mimic, however there was no effect in the cells containing EGR1 MUT sequence ( Figure 2H ), confirming that hsa-mir183 binds directly to the predicted sequence within EGR1 to prevent its transcription. In summary, these data support a model where BCR-ABL1-induced hsa-mir183 leads to a decrease of EGR1.
E2F1 signaling pathway is deregulated in CML SPC
To investigate how this hsa-mir183/EGR1 axis relates to transcriptional control of the cell cycle, specifically in relation to E2F1, we have performed in silico and in vitro Cell cycle related Gene Ontology 52 terms were significantly over-represented in the list of differentially expressed genes 32, 41 (Table S2) . E2F1 target genes identified as significantly differentially up-regulated in the first CML versus normal G0 transcriptional dataset (ArrayExpress accession E-MTAB-2508) are summarised in Figure 3Aii ; these same genes were shown to be significantly up-regulated in the second CML/normal G0 dataset by GSEA 45 ( Figure S2C ; NES=1.40, p=0.05). Interestingly, although E2F1, E2F2 and E2F3 share a high degree of functional redundancy, E2F2 and E2F3 were not differentially expressed between normal and CML cells ( Figure S2D ). Taken together, these in silico results suggest that E2F1 transcriptional targets are upregulated in quiescent CML SPC as compared to quiescent normal SPC.
To validate these in silico findings, we next performed in vitro functional experiments.
Up-regulation of E2F1 mRNA in CML SPC was confirmed by Q-PCR ( Figure 4A ). As expected, given that Rb protein phosphorylation (i.e. Rb inactivation) often coincides with E2F1 up-regulation, 53 phospho-Rb (inactive) was high in CML SPC ( Figure 4B , raw data provided in Table S4 ). The higher activity of E2F1 in CML SPC, in terms of cell To determine whether hsa-mir183/EGR1 were involved in E2F1 regulation of the cell cycle, we again knocked-down hsa-mir183 and observed a decrease in E2F1 and an increase in p21 mRNA levels, suggesting that the up-regulation of E2F1 was mediated by hsa-mir183, presumably through EGR1 ( Figure 3B ). To confirm this we, knockeddown EGR1 using siRNA which indeed caused an increase in E2F1 and CDK1 mRNA levels compared to control ( Figure 3C ).
These data therefore support a model whereby BCR-ABL1-induced hsa-mir183 expression leads to a decrease of EGR1 expression, which in turn results in the upregulation of E2F1 activity in CML SPC ( Figure 3D ).
E2F1 regulation is dependent on BCR-ABL1 kinase activity
To investigate whether E2F1 regulation in CML SPC was BCR-ABL1 kinase dependent as found for hsa-mir183 (Figure 2) , we compared transcriptional data for SPC ±TKI Figure S4 ) were significantly decreased. To determine whether the BCR-ABL1 driven regulation of E2F1 in the SPC of patients was sensitive to TKI therapy in vivo, we interrogated transcriptomic data from CML CD34 + cells harvested from six patients, before and at 7d after imatinib treatment (GEO accession GSE12211). 30 We observed that significantly more of the E2F1 targets were down-regulated by TKI in vivo than expected by chance (29 of 54, q=6.48x10 -24 ). To confirm that these effects were the result of BCR-ABL1 kinase inhibition rather than an enrichment for resistant leukemic cells, CML SPC were treated for 7d with dasatinib, washed and cultured for a further three days without drug; levels of E2F1 and CDK1 were restored following wash-out ( Figure 4E ). Similar behavior was seen in other representative E2F1 target genes ( Figure S5A ). Taken together, these data suggest that E2F1 regulation in CML SPC is BCR-ABL1 kinase dependent. Interestingly, E2F1 target genes were similarly deregulated in primary CD34 + CML versus normal PB samples, for both TKI-responders (R) and TKI-non-responders (NR) (GEO accession GSE14671): 33 random sampling demonstrated that E2F1 targets were significantly more correlated across TKI-R and NR than we would expect by chance (r=0.70, q<0.001) ( Figure S5B ). The same result was found for aggressive and indolent CML samples (ArrayExpress accession E-MIMR-17) (r=0.73, q<0.001) ( Figure S5C ). 34 Together, these analyses indicate that the E2F1 dependent deregulation observed in our unselected CML samples is also present in TKI-NR and aggressive CML phenotypes, and that targeting this deregulation may have wide clinical scope.
E2F1 is dispensable for normal SPC survival
Before considering the hsa-mir-183/EGR1/E2F1 axis for therapeutic targeting in CML SPC we first wished to confirm that targeting E2F1 would not be detrimental to normal SPC homeostasis using E2f1 -/-mice. 17 The reconstitution capacity of normal SPC 
E2F1 is required for CML SPC survival in vitro
We next asked whether increased activity of E2F1 in CML SPC led to an increased dependency on E2F1 for survival. E2F1 was knocked-down in normal and CML SPC using a GFP-lentiviral shRNA. The GFP + CD34 + 38 -cells showed a significant decrease in E2F1 expression in both normal and CML cells, and increase in p21 mRNA in CML ( Figure 6A-B) . In CFC assays, the number of colonies derived from CML, but not normal, SPC was significantly decreased, suggesting that E2F1 is required for CML SPC colony forming potential (Figure 6Ci-iii) . Furthermore, knockdown of E2F1 inhibited proliferation of CML SPC to a similar extent as the colcemid control ( Figure 6D ). E2F1 depletion also induced a significant increase in cell death in CML, but not in normal SPC, as indicated by an increased percentage of Annexin-V + cells ( Figure 6E ). These data suggest that E2F1 is required for CML SPC survival and proliferation in vitro. The efficacy of the knock-down system and the subsequent effects in primary CML cells using was corroborated using different sets of shRNAs ( Figure S7A -B).
p53 is known to mediate cell cycle arrest and apoptosis in primary mouse fibroblasts with triple inactivation of E2f1/2/3. 25 Given this and the increase in p21 mRNA levels we observed following E2F1 knockdown, we investigated whether the cell cycle arrest and apoptosis upon depletion of E2F1 in CML SPC was mediated by p53 activation. CML SPC were transfected with an E2F1-specific siRNA or control sequence. While the level of E2F1 was decreased, the level of p53 protein was unchanged ( Figure S8Ai ).
However, an increase in Serine 15 (Ser15) phosphorylation on p53, a crucial site for the induction of cell cycle arrest, 54 was observed in SPC transduced with E2F1 siRNA compared to control ( Figure S8Aii ), suggesting that a decrease in E2F1 resulted in activation of p53. The efficacy of the knock-down system in primary CD34 + CML cells was confirmed using different sets of siRNA ( Figure S8B ).
To determine whether the changes in apoptosis in E2F1 knock-down CML SPC were the direct result of increased p53 activity, we performed knock-downs of E2F1 and p53, separately and in combination, with the double knock-down resulting in reduced E2F1 on a background of low p53 (expression of Puma and CDK1 were measured as representative indicators of p53 and E2F1 activity, respectively) ( Figure S8C ). p53 activity was higher upon E2F1 knock-down, while E2F1 activity was higher upon p53 knock-down. In the combination, no changes were seen in either the p53 or E2F1 downstream targets. Three days after transfection, apoptosis levels were significantly higher in the E2F1 knock-down, whereas there was no difference in the combination relative to control ( Figure S8D ). These data imply that the apoptosis and inhibition of proliferation arising from E2F1 knock-down in CML SPCs is mediated by p53.
Discussion
The oncogenic role of the E2F family members has previously been reported. 53, [55] [56] [57] E2F3 has been shown to play a role in controlling BCR-ABL1-driven leukemogenesis in vitro and in vivo, 23 while in vitro studies have indicated that E2F1 regulates the cell cycle of BCR-ABL1 positive cell lines. 58, 59 Here, we have employed primary patient-derived cells to demonstrate that E2F1 is required for the survival of CML but not normal SPC in vitro, and that E2F1 is regulated in CML SPC via the BCR-ABL1/hsa-mir183/EGR1 axis.
In CML SPC, E2F1 was the effector of a novel signaling pathway mediated by upregulation of hsa-mir183 and inhibition of its direct target EGR1. Indeed, recent evidence demonstrates that leukemia development is accelerated in the absence of EGR1 in a CML mouse model. 38 E2F1 up-regulation was BCR-ABL1 kinase dependent and its inhibition led to a decrease in colony forming potential, cell cycle arrest and induction of p53-mediated cell death, suggesting the dependency of leukemic SPC on E2F1.
Our data provide mechanistic insight into how CML SPC death induced by E2F1 inhibition may be mediated by p53. We have previously shown that the apoptotic activity of p53 is down-regulated in leukemic stem cells 27 and here we have demonstrated that its activity is increased upon inhibition of E2F1 in CML SPC (by showing that increased cell death in E2F1 knock-down CML SPC was associated with post-transcriptional modification of Ser15 on p53). To investigate the functional link between E2F1 and p53
in CML SPC, we hypothesized that cell death due to E2F1 knock-down might be rescued by simultaneous knock-down of p53. While these data suggest that knockdown of p53 may be sufficient to ameliorate cell death of E2F1 deficient CML SPC, further work will be required to definitively prove the relevance of this mechanism is CML.
Despite E2F1 up-regulation being BCR-ABL dependent, recent work in single CML SPCs has demonstrated that E2F1 signalling and proliferation-associated gene expression are active in a subpopulation of BCR-ABL + cells that persist following TKI treatment 14 . This suggests that therapeutic intervention (via therapeutic targeting of E2F1 or the other components of our model), could address a pressing unmet clinical need for CML patients.
Of relevance to designing a novel therapy for CML, our work indicated that normal SPC
were not affected by inhibition of the E2F1 pathway, suggesting a potential therapeutic window and CML specificity. Although our studies suggest that inhibition of E2F1 itself may represent a promising therapeutic target, transcription factors are notoriously challenging in drug development and alternative routes to target the BCR-ABL1/hsa-mir183/EGR1/E2F1 axis may prove to be more tractable. Future investigations will explore the therapeutic potential of the BCR-ABL1/hsa-mir183/EGR1/E2F1 axis in CML.
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